Deadline Alert: Merck & Co (MRK) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Merck & Co (“Merck” or the “Company”) (
NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”).
Deadline Approaching: Merck & Co (MRK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (
NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the FirmNEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Edison International (
NYSEEIX), Elastic N.V.
NYSE:ESTCNYSEESTC)
(NASDAQ:NTLANASDAQNTLA
, and Merck & Co., Inc. (NYSE: MRKNYSE
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or “the Company”) (
NYSEMRK) and certain of its officers.
Law Offices of Frank R. Cruz Encourages Merck & Co (MRK) Investors to Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (
NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Merck (
NYSEMRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 23, 2025.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Merck & Co (“Merck” or the “Company”) (
NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
Merck (
NYSEMRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST.
Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (
NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co (“Merck” or the “Company”) (
NYSEMRK) investors concerning the Company’s possible violations of the federal securities laws.
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Merck & Co (“Merck” or the “Company”) (
NYSEMRK) investors concerning the Company’s possible violations of federal securities laws.
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Merck & Co (“Merck” or the “Company”) (
NYSEMRK) on behalf of investors concerning the Company’s possible violations of federal securities laws.
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their RightsNEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Merck & Co., Inc. (“Merck” or the “Company”) (
NYSEMRK) between February 3, 2022 and February 3, 2025, inclusive.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRKSAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (
NYSEMRK) securities between February 3, 2022 and February 3, 2025. Merck is a global healthcare company.
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
Merck (
NYSEMRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monotherapy for:
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or “the Company”) (
NYSEMRK) and certain of its officers.
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (
NYSEMRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit. Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck as well as certain of Merck’s top executives with violations of the Securities Exchange Act of 1934.
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. (“Merck” or “the Company”) (
NYSEMRK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (
NYSEMRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit. Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck and certain of Merck’s top executives with violations of the Securities Exchange Act of 1934.
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Merck & Co., Inc. (
NYSEMRK) between February 3, 2022, and February 3, 2025. Merck describes itself as a “global healthcare company that operates through two segments, Pharmaceutical and Animal Health, with a significant focus on prescription medications.”
